Developer docs
API playgroundTry for free, no card

Search company profiles

BEONE MEDICINES

Full company profile

uuid02f88x9

Namestring
BEONE MEDICINES
Legal namestring
BeOne Medicines I GmbH
Company typeenum
Public
Founded yearint
2018
Descriptiontext

BeOne Medicines is a global oncology therapeutics company that develops and commercializes treatments for blood cancers and solid tumors, with a pipeline spanning small molecules, biologics, antibody drug conjugates (ADCs), and protein degradation via CDACs. Its three internally developed approved medicines—Brukinsa (zanubrutinib), a BTK inhibitor; Tevimbra (tislelizumab), a PD-1 inhibitor; and tarlatamab, a bispecific T-cell engager developed with Amgen—are sold across 80+ countries, supported by a clinical operations footprint spanning 45+ countries and 30,000+ enrolled patients. The company supplements internal R&D with licensing and collaboration deals, including a $1.9B-milestone agreement with Huahui Health for the HH160 trispecific antibody and combination-trial partnerships with Senhwa Biosciences.

BeOne generates revenue through two streams: direct pharmaceutical product sales of approved oncology medicines to healthcare providers and national health systems, and licensing/milestone payments including upfront fees, development/regulatory/sales milestones, and tiered royalties on partnered products. Distribution runs through field medical and senior medical advisors engaging healthcare providers directly, supplemented by reimbursement negotiations with health technology assessment bodies (NICE, SMC, NCPE, Ireland HSE). The company is publicly traded under ticker ONC as the rebrand of BeiGene, operates across six continents with approximately 12,000 employees including 1,200+ in research, and pursues a vertical segmentation approach serving haematology and solid tumour patient populations globally.

The company's competitive positioning rests on scientific execution speed, broad modality coverage, and global commercial reach. Recent strategic activity—including tarlatamab's China approval, tislelizumab's Irish reimbursement, FDA Orphan Drug Designation for a hepatocellular carcinoma candidate, and the Huahui Health trispecific antibody deal—indicates continued offensive expansion across geographies, modalities, and indications rather than defensive retrenchment.

Short descriptiontext

BeOne Medicines is a global oncology company that develops and commercializes cancer therapeutics, including the approved drugs Brukinsa, Tevimbra, and tarlatamab, across 80+ countries for blood and solid tumor patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, cancer drug development, immuno-oncology drugs, hematologic malignancy treatment, clinical trial research
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

BeOne Medicines generates revenue through the sale of internally developed oncology medicines globally, including Brukinsa (zanubrutinib), tislelizumab (marketed as Tevimbra), and tarlatamab. Products are sold in 80+ countries following regulatory approvals.

beonemedicines.co.uk
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue generated through licensing agreements including upfront payments, option exercise payments, development/regulatory/sales milestones, and tiered royalties on net sales from partnered products like HH160.

thehindubusinessline.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Tevimbra
Description

Brand name for tislelizumab, a PD-1 inhibitor approved for advanced oesophageal cancer and other indications.

pharmiweb.com
+1 more record
Core offering1 text field

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes innovative cancer therapeutics for both hematologic malignancies and solid tumors. The company's portfolio includes three internally developed approved medicines — Brukinsa (zanubrutinib, a BTK inhibitor), Tislelizumab (Tevimbra, a PD-1 inhibitor), and Tarlatamab (a bispecific T-cell engager) — supported by a deep pipeline of candidates including HH160 and BGB-16673, with regulatory approvals across 80+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 3 RATIONALE-306 trial demonstrated median overall survival of 17.2 months vs 10.6 months with chemotherapy alone for tislelizumab in advanced oesophageal squamous cell carcinoma
+1 more record
Product overview1 text field

BeOne Medicines is a global oncology company offering a portfolio of approved and investigational cancer medicines. The company's core products include Brukinsa (zanubrutinib), a BTK inhibitor approved across 80+ countries; Tislelizumab (Tevimbra), a PD-1 inhibitor for solid tumors; and tarlatamab, a bispecific T-cell engager for small cell lung cancer. Pipeline candidates include HH160, a trispecific antibody targeting PD-1/CTLA-4/VEGF-A for oncology, and BGB-16673 in Phase 1/2 trials for marginal zone lymphoma. The company operates clinical trials across 45+ countries and regions with approximately 30,000 patients enrolled.

Product and service5 records
1Brukinsa (zanubrutinib)
CategoryCore oncology product
Description

A BTK (Bruton's tyrosine kinase) inhibitor approved for the treatment of various hematologic malignancies, marketed across 80+ countries as one of BeOne's three internally developed medicines.

2Tislelizumab (Tevimbra)
CategoryCore oncology product
Description

A PD-1 inhibitor immunotherapy drug for treating advanced solid tumors including oesophageal squamous cell carcinoma and multiple other malignancies, marketed under the brand name Tevimbra.

3Tarlatamab
CategoryCore oncology product
Description

A bispecific T-cell engager approved in China for adult patients with extensive-stage small cell lung cancer whose disease has progressed after chemotherapy; BeOne serves as development and commercialization partner for Amgen in the Chinese market.

4HH160
CategoryPipeline oncology candidate
Description

A novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy, licensed globally from Huahui Health and utilizing the PolyBoost multispecific antibody platform; BeOne holds exclusive worldwide rights to develop, manufacture, and commercialize.

5BGB-16673
CategoryPipeline oncology candidate
Description

A drug candidate in Phase 1/2 clinical development for marginal zone lymphoma treatment, part of BeOne's expanding pipeline of targeted oncology therapies using protein degradation approaches.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy. BeOne Medicines pays USD 20 million upfront, USD 100 million upon option exercise, and up to USD 1.9 billion in milestones plus tiered royalties. Collaboration leverages Huahui Health's PolyBoost platform with BeOne's global oncology development expertise.

2Senhwa Biosciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Clinical trial collaboration evaluating Senhwa's first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' PD-1 inhibitor tislelizumab across multiple advanced solid tumors including pancreatic cancer, colorectal cancer, and melanoma.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-12
Description

Development and commercialization partnership for tarlatamab, a bispecific T-cell engager. BeOne Medicines serves as the development and commercialization partner in China, where the therapy received regulatory approval from China's National Medical Products Administration for treating extensive-stage small cell lung cancer.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Operates a broad oncology portfolio including PD-1/PD-L1 inhibitors, ADCs, and hematology assets. Pfizer is a broader incumbent rather than a focused peer, but competes in many of the same solid-tumor and hematology indications as BeOne.

TypeDirect peer
Description

Markets Imbruvica (ibrutinib, BTK inhibitor) and Venclexta (BCL-2) — direct competitors to BeOne's Brukinsa in hematologic malignancies. AbbVie's established hematology commercial infrastructure is the primary incumbent BeOne must displace in BTK-driven indications.

TypeDirect peer
Description

Keytruda (pembrolizumab) is the global PD-1 standard of care and the most direct competitive threat to tislelizumab across oncology indications. Merck's oncology commercial reach and pipeline depth make it the primary benchmark for BeOne's IO franchise trajectory.

TypeBroad incumbent
Description

Global oncology leader with checkpoint inhibitors (Tecentriq), HER2/oncology ADCs, and a deep hematology franchise. Competes with BeOne across both immuno-oncology and ADC modalities and serves as a benchmark for global oncology commercial scale.

TypeDirect peer
Description

Global oncology major with a directly overlapping portfolio across PD-1/PD-L1 inhibitors (Imfinzi), ADCs (Enhertu, Datroway), and targeted therapies across hematology and solid tumors. AstraZeneca competes head-to-head with BeOne in immuno-oncology and ADC modalities and recruits from a similar talent base (per the Anurag Gupta hire background).

6Bristol Myers Squibb
TypeDirect peer
Description

Operates Opdivo (PD-1) and a leading hematology/oncology franchise (Pomalyst, Reblozyl, Empliciti). BMS directly competes with BeOne in both PD-1 solid-tumor indications and B-cell hematologic malignancies targeted by Brukinsa.

TypeDirect peer
Description

Tarlatamab development partner for the China market and a broad oncology/biologics player (Blincyto, Lumakras, Imdelltra). Comparable to BeOne as a large-cap biologics and bispecific T-cell engager developer, and a strategic partner whose priorities directly affect one of BeOne's three core assets.

TypeBroad incumbent
Description

Significant oncology presence in multiple myeloma (Darzalex, Carvykti) and prostate cancer (Erleada, Akeega). J&J competes with BeOne in hematology and is a benchmark for global commercial reach in oncology.

TypeBroad incumbent
Description

Oncology franchise anchored by Trodelvy (ADC) and growing hematology assets post-Immunomedics acquisition. Gilead competes with BeOne in solid-tumor ADC space and shares the multi-modality innovator playbook.

TypeBroad incumbent
Description

Major oncology player with radioligand therapy (Pluvicto), targeted therapies (Kisqali, Scemblix), and CAR-T (Kymriah). Comparable to BeOne as a globally diversified innovator with multi-modality oncology ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BEONE MEDICINES

Oncology Pharmaceuticalsbeonemedicines.co.uk

BeOne Medicines is a global oncology company that develops and commercializes cancer therapeutics, including the approved drugs Brukinsa, Tevimbra, and tarlatamab, across 80+ countries for blood and solid tumor patients.

What BEONE MEDICINES does

BeOne Medicines is a global oncology therapeutics company that develops and commercializes treatments for blood cancers and solid tumors, with a pipeline spanning small molecules, biologics, antibody drug conjugates (ADCs), and protein degradation via CDACs. Its three internally developed approved medicines—Brukinsa (zanubrutinib), a BTK inhibitor; Tevimbra (tislelizumab), a PD-1 inhibitor; and tarlatamab, a bispecific T-cell engager developed with Amgen—are sold across 80+ countries, supported by a clinical operations footprint spanning 45+ countries and 30,000+ enrolled patients. The company supplements internal R&D with licensing and collaboration deals, including a $1.9B-milestone agreement with Huahui Health for the HH160 trispecific antibody and combination-trial partnerships with Senhwa Biosciences.

BeOne generates revenue through two streams: direct pharmaceutical product sales of approved oncology medicines to healthcare providers and national health systems, and licensing/milestone payments including upfront fees, development/regulatory/sales milestones, and tiered royalties on partnered products. Distribution runs through field medical and senior medical advisors engaging healthcare providers directly, supplemented by reimbursement negotiations with health technology assessment bodies (NICE, SMC, NCPE, Ireland HSE). The company is publicly traded under ticker ONC as the rebrand of BeiGene, operates across six continents with approximately 12,000 employees including 1,200+ in research, and pursues a vertical segmentation approach serving haematology and solid tumour patient populations globally.

The company's competitive positioning rests on scientific execution speed, broad modality coverage, and global commercial reach. Recent strategic activity—including tarlatamab's China approval, tislelizumab's Irish reimbursement, FDA Orphan Drug Designation for a hepatocellular carcinoma candidate, and the Huahui Health trispecific antibody deal—indicates continued offensive expansion across geographies, modalities, and indications rather than defensive retrenchment.

BEONE MEDICINES firmographics

Firmographics
Name
BEONE MEDICINES
Legal name
BeOne Medicines I GmbH
Website
https://beonemedicines.co.uk
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
10,001+ employees
Short description
BeOne Medicines is a global oncology company that develops and commercializes cancer therapeutics, including the approved drugs Brukinsa, Tevimbra, and tarlatamab, across 80+ countries for blood and solid tumor patients.
Ownership category
akta.pro rank

BEONE MEDICINES industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Cancer drug development
  • Immuno-oncology drugs
  • Hematologic malignancy treatment
  • Clinical trial research

Where BEONE MEDICINES is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

BEONE MEDICINES business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: BeOne Medicines generates revenue through the sale of internally developed oncology medicines globally, including Brukinsa (zanubrutinib), tislelizumab (marketed as Tevimbra), and tarlatamab. Products are sold in 80+ countries following regulatory approvals.
  2. Licensing and Milestone Payments: Revenue generated through licensing agreements including upfront payments, option exercise payments, development/regulatory/sales milestones, and tiered royalties on net sales from partnered products like HH160.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

BEONE MEDICINES product offering

Product offering

Core offering

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes innovative cancer therapeutics for both hematologic malignancies and solid tumors. The company's portfolio includes three internally developed approved medicines — Brukinsa (zanubrutinib, a BTK inhibitor), Tislelizumab (Tevimbra, a PD-1 inhibitor), and Tarlatamab (a bispecific T-cell engager) — supported by a deep pipeline of candidates including HH160 and BGB-16673, with regulatory approvals across 80+ countries.

Product overview

BeOne Medicines is a global oncology company offering a portfolio of approved and investigational cancer medicines. The company's core products include Brukinsa (zanubrutinib), a BTK inhibitor approved across 80+ countries; Tislelizumab (Tevimbra), a PD-1 inhibitor for solid tumors; and tarlatamab, a bispecific T-cell engager for small cell lung cancer. Pipeline candidates include HH160, a trispecific antibody targeting PD-1/CTLA-4/VEGF-A for oncology, and BGB-16673 in Phase 1/2 trials for marginal zone lymphoma. The company operates clinical trials across 45+ countries and regions with approximately 30,000 patients enrolled.

Differentiator

Problem solved

Functional benefit

Brands

  • Tevimbra: Brand name for tislelizumab, a PD-1 inhibitor approved for advanced oesophageal cancer and other indications.
  • Brukinsa

Products and services

  • Brukinsa (zanubrutinib) A BTK (Bruton's tyrosine kinase) inhibitor approved for the treatment of various hematologic malignancies, marketed across 80+ countries as one of BeOne's three internally developed medicines.
  • Tislelizumab (Tevimbra) A PD-1 inhibitor immunotherapy drug for treating advanced solid tumors including oesophageal squamous cell carcinoma and multiple other malignancies, marketed under the brand name Tevimbra.
  • Tarlatamab A bispecific T-cell engager approved in China for adult patients with extensive-stage small cell lung cancer whose disease has progressed after chemotherapy; BeOne serves as development and commercialization partner for Amgen in the Chinese market.
  • HH160 A novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy, licensed globally from Huahui Health and utilizing the PolyBoost multispecific antibody platform; BeOne holds exclusive worldwide rights to develop, manufacture, and commercialize.
  • BGB-16673 A drug candidate in Phase 1/2 clinical development for marginal zone lymphoma treatment, part of BeOne's expanding pipeline of targeted oncology therapies using protein degradation approaches.

Quantifiable outcome

  • Phase 3 RATIONALE-306 trial demonstrated median overall survival of 17.2 months vs 10.6 months with chemotherapy alone for tislelizumab in advanced oesophageal squamous cell carcinoma
  • +1 more outcomes

Companies that use BEONE MEDICINES

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

BEONE MEDICINES technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BEONE MEDICINES partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Huahui HealthcoreStrategic or Co-development Partner · 5 May 2026Global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy. BeOne Medicines pays USD 20 million upfront, USD 100 million upon option exercise, and up to USD 1.9 billion in milestones plus tiered royalties. Collaboration leverages Huahui Health's PolyBoost platform with BeOne's global oncology development expertise.
  • Senhwa BiosciencesminorStrategic or Co-development Partner · 5 May 2026Clinical trial collaboration evaluating Senhwa's first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' PD-1 inhibitor tislelizumab across multiple advanced solid tumors including pancreatic cancer, colorectal cancer, and melanoma.
  • AmgencoreStrategic or Co-development Partner · 12 April 2026Development and commercialization partnership for tarlatamab, a bispecific T-cell engager. BeOne Medicines serves as the development and commercialization partner in China, where the therapy received regulatory approval from China's National Medical Products Administration for treating extensive-stage small cell lung cancer.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

BEONE MEDICINES competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Operates a broad oncology portfolio including PD-1/PD-L1 inhibitors, ADCs, and hematology assets. Pfizer is a broader incumbent rather than a focused peer, but competes in many of the same solid-tumor and hematology indications as BeOne.
  • Roche: Global oncology leader with checkpoint inhibitors (Tecentriq), HER2/oncology ADCs, and a deep hematology franchise. Competes with BeOne across both immuno-oncology and ADC modalities and serves as a benchmark for global oncology commercial scale.
  • Johnson & Johnson: Significant oncology presence in multiple myeloma (Darzalex, Carvykti) and prostate cancer (Erleada, Akeega). J&J competes with BeOne in hematology and is a benchmark for global commercial reach in oncology.
  • Gilead Sciences: Oncology franchise anchored by Trodelvy (ADC) and growing hematology assets post-Immunomedics acquisition. Gilead competes with BeOne in solid-tumor ADC space and shares the multi-modality innovator playbook.
  • Novartis: Major oncology player with radioligand therapy (Pluvicto), targeted therapies (Kisqali, Scemblix), and CAR-T (Kymriah). Comparable to BeOne as a globally diversified innovator with multi-modality oncology ambitions.

Direct peers

  • AbbVie: Markets Imbruvica (ibrutinib, BTK inhibitor) and Venclexta (BCL-2) — direct competitors to BeOne's Brukinsa in hematologic malignancies. AbbVie's established hematology commercial infrastructure is the primary incumbent BeOne must displace in BTK-driven indications.
  • Merck & Co. Keytruda (pembrolizumab) is the global PD-1 standard of care and the most direct competitive threat to tislelizumab across oncology indications. Merck's oncology commercial reach and pipeline depth make it the primary benchmark for BeOne's IO franchise trajectory.
  • AstraZeneca: Global oncology major with a directly overlapping portfolio across PD-1/PD-L1 inhibitors (Imfinzi), ADCs (Enhertu, Datroway), and targeted therapies across hematology and solid tumors. AstraZeneca competes head-to-head with BeOne in immuno-oncology and ADC modalities and recruits from a similar talent base (per the Anurag Gupta hire background).
  • Bristol Myers Squibb: Operates Opdivo (PD-1) and a leading hematology/oncology franchise (Pomalyst, Reblozyl, Empliciti). BMS directly competes with BeOne in both PD-1 solid-tumor indications and B-cell hematologic malignancies targeted by Brukinsa.
  • Amgen: Tarlatamab development partner for the China market and a broad oncology/biologics player (Blincyto, Lumakras, Imdelltra). Comparable to BeOne as a large-cap biologics and bispecific T-cell engager developer, and a strategic partner whose priorities directly affect one of BeOne's three core assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

BEONE MEDICINES social profiles

Digital presence

BEONE MEDICINES financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BEONE MEDICINES leadership team

Management profile

Number of profiles

Profiles11 records

BEONE MEDICINES funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BEONE MEDICINES M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BEONE MEDICINES

What does BEONE MEDICINES do?

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes innovative cancer therapeutics for both hematologic malignancies and solid tumors. The company's portfolio includes three internally developed approved medicines — Brukinsa (zanubrutinib, a BTK inhibitor), Tislelizumab (Tevimbra, a PD-1 inhibitor), and Tarlatamab (a bispecific T-cell engager) — supported by a deep pipeline of candidates including HH160 and BGB-16673, with regulatory approvals across 80+ countries.

Is BEONE MEDICINES a public or private company?

BEONE MEDICINES is a public company. It is classified as public and is currently operating.

When was BEONE MEDICINES founded?

BEONE MEDICINES was founded in 2018. It employs 10,001+ people.

Where is BEONE MEDICINES based?

BEONE MEDICINES is headquartered in London, United Kingdom, in the Europe region.

How does BEONE MEDICINES make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments.

Who are BEONE MEDICINES's main competitors?

Broad incumbents on record are Pfizer, Roche, Johnson & Johnson, Gilead Sciences and Novartis. Direct peers are AbbVie, Merck & Co., AstraZeneca, Bristol Myers Squibb and Amgen.

Does BEONE MEDICINES have an API?

No public API is recorded for BEONE MEDICINES.

What industry is BEONE MEDICINES in?

BEONE MEDICINES's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup BusinessLeucemia linfatica cronica, l’arte dà voce all’esperienza dei pazientiArtist Angelo Orazio Pregoni's work 'Natura viva' was exhibited at the 61st Venice Biennale, supported by BeOne Medicines, to give voice to patients with chronic lymphocytic leukemia (CLL). The painting depicts a patient figure surrounded by iconic figures, reflecting the complex emotional and relational experience of the disease. BeOne highlighted that while research has improved treatments, the human dimension of care remains essential.InvestorsBiotech Leader BeOne Medicines Poised To Hit Early Buy PointsBeOne Medicines is poised to clear an early buy point, with Q2 earnings up 125% to $2.05 per share and Brukinsa sales rising 31% to $1.2 billion. Q3 results are expected in early November, with analysts projecting EPS of $1.87 and revenue of $1.75 billion.EleconomistaJosé María Pons, nuevo director general de BeOne Medicines en IberiaBeOne Medicines appointed José María Pons as its new general director for Iberia, leading operations in Spain and Portugal. He brings over 15 years of pharmaceutical experience, previously leading Novartis' Hematology business unit in Spain. The company aims to strengthen its Iberian leadership during a growth phase with about 150 employees.OncLiveMANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemotherapy in MCLThe MANGROVE phase 3 trial found zanubrutinib plus rituximab reduced progression or death risk by 43% versus bendamustine-rituximab in frontline mantle cell lymphoma. The hazard ratio was 0.57 (95% CI, 0.43-0.76; P < .0001), with immature OS data favoring the combination. BeOne Medicines plans to submit data for regulatory approval in the second half of 2026.EleconomistaBeOne impulsa 'No Patient Like Me' para promover una atención más personalizada en la leucemia linfocítica crónicaBeOne Medicines launched 'No Patient Like Me' with patient groups to promote personalized care in chronic lymphocytic leukemia. The campaign highlights that three of four patients want shared decision-making, but only one of five feels they achieve it. It aims to help patients and doctors consider individual priorities in treatment choices.FinancialContent Business PageBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceBeOne Medicines will present at the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The company, a global oncology firm, will also host a live webcast accessible from its investors section.YicaiglobalBeOne Medicines Agrees to Cut Price of Esophageal Cancer Drug in USBeOne Medicines agreed to lower the price of Tevimbra under the US Medicaid program, joining nine other pharma companies. The company estimates the agreement covers about 8% of eligible patients, and shares fell 1.2% in Shanghai. The US government will encourage more manufacturers to make similar arrangements.Business Wire BlogBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceBeOne Medicines will present at the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The live webcast will be available on the company's website, with an archived version also provided.MarketScreenerBeone Medicines Announces Positive Topline Results from Second Interim Analysis of Phase 3 Herizon-Gea-01 Trial Evaluating Ziihera in Combination with Chemotherapy with and Without Tevimbra as First-LBeOne Medicines announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial, showing Ziihera plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy. The FDA approved the regimen on August 25, 2026, as the first immunotherapy-based first-line treatment for HER2+ GEA with median OS exceeding two years.FinancialContent Business PageBeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer MedicinesBeOne Medicines announced a voluntary agreement with the U.S. Government to expand patient access to innovative cancer therapies while strengthening its domestic manufacturing footprint. The deal includes an exemption from Section 232 pharmaceutical tariffs in recognition of the company's $1 billion total U.S. manufacturing investment, which features a recent $300 million expansion in New Jersey. This initiative supports the company's participation in the GENEROUS pricing model and aims to enhance supply continuity for its oncology pipeline.